Galderma (SWX:GALD) Stock May Be 48% Undervalued After China Study Results

Galderma Group has delivered a 10.1% return over the past year, and the move raises a simple question for anyone watching the stock today. Is the current share price adequately explained by the cash flows investors can reasonably expect the business to generate over time?

• The 10.1% gain over the last 12 months puts real weight on whether Galderma Group’s recent share price now fully bakes in its cash flow profile.
• Fresh study data on Restylane Volyme in China may support expectations for future cash generation if it helps broaden Galderma Group’s presence in one of the faster growing aesthetics markets.
• What if you looked at Galderma Group through its earnings instead? See why Galderma Group's 52.0x P/E tells a different valuation story.

The issue now is whether Galderma Group’s current market price lines up with its intrinsic value based on projected cash flows under a Discounted Cash Flow (DCF) lens.

If you want a broader watchlist alongside Galderma Group while you research its cash flows, a focused screen of 180 high quality undervalued stocks can be a useful next step.

Does Galderma Group Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model values Galderma Group based on the cash it is expected to generate for shareholders over time. On this view, the latest twelve month free cash flow sits at about $968 million, and the forecast path assumes that figure grows rather than contracts over the next decade.

Projected free cash flows reach into the low single digit billions of dollars in the 2030s, which implies the business is treated more like a steadily expanding cash generator than a turnaround story. Because these projected cash flows, when discounted back, point to an intrinsic value substantially above the current CHF158.15 share price, the model suggests investors are not paying a premium for that growth profile. Positive Restylane Volyme study results in China fit that story, because broader aesthetics usage in a large market is consistent with the stronger cash generation baked into the DCF output. Find out what Galderma Group could be worth using our Discounted Cash Flow (DCF) estimate.

The Galderma Group Narrative: What Would Justify Today's Price?

Narratives for Galderma Group pick up where the DCF puzzle leaves off and explain which paths for growth, margins and earnings would need to occur for the stock to be worth clearly more or clearly less than today’s price on Simply Wall St’s Community page. Rather than stopping at a single output from a ratio or valuation model, they describe the future assumptions that number is based on so you can judge over time whether reality is tracking that script.

Bulls and bears on Galderma Group are looking at the same products and markets, yet they reach very different conclusions on valuation risk.

Bull case: 18% undervalued

"The strong uptake and market share gains of newly launched products like Nemluvio and Relfydess, driven by their differentiated clinical profiles and positive physician reception…"

Discover why this Narrative puts Galderma Group at 18% undervalued.

Bear case: 15% overvalued

"Heightened regulatory scrutiny and the risk of future global price controls on pharmaceuticals and aesthetic treatments threaten to compress Galderma's margins…"

Explore why this Narrative puts Galderma Group at 15% overvalued.

Galderma Group’s price is only one piece of the investment puzzle

Before you stop at what Galderma Group might be worth on cash flows alone, it is worth asking who is steering the business and how their pay packets line up with your interests. See who runs Galderma Group and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com